Related Experiment Video
Updated: Mar 28, 2026
05:48
The Adventures of Fundi Intervention Based on the Cognitive and Emotional Processing in Attention Deficit Hyperactive Disorder Patients
Published on: June 12, 2020
6.6K
[Effect of extended-release methylphenidate on the ecological executive function for attention deficit hyperactivity
Ying Qian1, Qing-jiu Cao, Yu-feng Wang
1Institute of Mental Health, Peking University, Beijing 100083, China.
Summary
Extended-release methylphenidate improved executive functions in children with attention deficit hyperactivity disorder (ADHD). Improvements in metacognition correlated with reduced inattentive symptoms, but not necessarily all ADHD core symptoms.
Area of Science:
- Neuroscience
- Child Psychology
- Pharmacology
Background:
- Attention deficit hyperactivity disorder (ADHD) is a neurodevelopmental disorder characterized by persistent patterns of inattention and/or hyperactivity-impulsivity.
- Executive functions, crucial for goal-directed behavior, are often impaired in individuals with ADHD.
- Ecological executive function refers to the ability to apply executive functions in real-world settings.
Purpose of the Study:
- To investigate the efficacy of extended-release methylphenidate (Concerta) in enhancing ecological executive function in children diagnosed with ADHD.
- To examine the relationship between improvements in ecological executive function and the amelioration of core ADHD symptoms.
Main Methods:
- An open-trial study involving 26 children with ADHD (aged 8-14 years) treated with extended-release methylphenidate (18-54 mg/d) for 4-6 weeks.
- Assessment of ecological executive function and ADHD symptoms using parent-reported Behavior Rating Inventory of Executive Function (BRIEF), ADHD-IV rating scale, and Conners rating scales before and after treatment.
Main Results:
- Significant reductions were observed in the mean raw scores for the Global Executive Composite (GEC), Metacognition Index (MI), working memory, monitoring, and inhibition subscales of the BRIEF post-treatment.
- The reduction rates of MI and its associated subscales showed a moderate correlation with the reduction rates of the inattentive subscale of the ADHD-IV rating scale (r=0.415-0.640, P<0.05).
- No significant correlation was found between the reduction rate of the inhibition subscale and the overall reduction in ADHD symptoms.
Conclusions:
- Extended-release methylphenidate demonstrates potential in improving ecological executive function in children with ADHD.
- The improvement in specific executive functions, such as inhibition, may not consistently parallel the reduction in core ADHD symptoms.
More Related Videos
10:02Event Related Potentials ERPs and other EEG Based Methods for Extracting Biomarkers of Brain Dysfunction: Examples from Pediatric Attention Deficit/Hyperactivity Disorder ADHD
Published on: March 12, 2020
17.0K
13:09Using Brain Activation nir-HEG/Q-EEG and Execution Measures CPTs in a ADHD Assessment Protocol
Published on: April 1, 2018
11.1K
Related Concept Videos
01:19Modified-Release Drug Delivery Systems: Overview
156
Modified-release dosage forms are designed to address the limitations of drugs with short biological half-lives. These forms maintain stable therapeutic drug concentrations over extended periods, reducing the need for frequent dosing. A consistent drug level helps minimize peak-trough fluctuations, which can reduce adverse effects, lower the risk of drug resistance, and improve overall treatment effectiveness.One common type of modified-release form is the extended-release (ER) formulation. ER...
156
01:30Attention-Deficit/Hyperactivity Disorder
1.3K
Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder characterized by persistent inattention, hyperactivity, and impulsivity. It affects approximately 5-8% of children globally, with around 60-70% of cases persisting into adulthood. ADHD has significant implications for educational attainment, social interactions, and occupational success.
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings....
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings....
1.3K
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
833
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
833
01:24Working Memory
1.2K
Working memory refers to a combination of components, including short-term memory and attention, that allow an individual to hold information temporarily as we perform cognitive tasks. It is an essential cognitive function that enables the execution of complex tasks such as problem-solving, comprehension, and reasoning. Unlike short-term memory, which simply involves the storage of information for a brief period, working memory involves the active manipulation and processing of this...
1.2K
01:28Adrenergic Agonists: Mixed-Action Agents
1.7K
Mixed-action adrenergic agonists, like ephedrine and pseudoephedrine, directly and indirectly affect adrenergic receptors. These agents stimulate adrenoceptors and indirectly release stored neurotransmitters, amplifying the adrenergic response.
Ephedrine and pseudoephedrine lack a catecholamine group, making them less susceptible to degradation by metabolic enzymes. They have increased oral bioavailability and lipophilicity, resulting in a longer duration of action. Their response is reduced by...
Ephedrine and pseudoephedrine lack a catecholamine group, making them less susceptible to degradation by metabolic enzymes. They have increased oral bioavailability and lipophilicity, resulting in a longer duration of action. Their response is reduced by...
1.7K
01:25Adrenergic Agonists: Indirect-Acting Agents
3.0K
Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
3.0K